Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation: a Prospective, Phase II Study by the SFGM-TC

NCT03948529 is registered in ClinicalTrials.gov with University Hospital, Lille as lead sponsor.

NCT NCT03948529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03948529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation: a Prospective, Phase II Study by the SFGM-TC
Lead sponsor
University Hospital, Lille
Phase
Phase 2
Overall status
Terminated
Start date
September 5, 2019
Completion date
August 21, 2023
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graft failure, leukemia